Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal CancerThierry André, Luis A. Díaz|New England Journal of Medicine|2020Cited by 2.9k
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 studyMichael J. Overman, Thierry André, Ray McDermott et al.|The Lancet Oncology|2017Cited by 2.8k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal CancerMichael J. Overman, Thierry André, Sara Lonardi et al.|Journal of Clinical Oncology|2018Cited by 2.1k
Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal CancerMarc Peeters, Jennifer Gansert, Timothy Price et al.|Journal of Clinical Oncology|2010Cited by 1k
Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 studyLuis A. Díaz, Thierry André|The Lancet Oncology|2022Cited by 872